PRC 062

Drug Profile

PRC 062

Latest Information Update: 25 Feb 2016

Price : $50

At a glance

  • Originator Purdue Pharma
  • Class Analgesics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Pain

Most Recent Events

  • 24 Feb 2016 No recent reports on development identified - Phase-III for Pain in Canada (unspecified route)
  • 31 Jul 2014 Purdue Pharma completes a phase III trial in non-cancer Pain in Canada (ISRCTN54273961)
  • 01 Nov 2013 Phase-III clinical trials in Pain (non-cancer pain) in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top